COVID-19

@forbes.com 3 years ago

Should You Buy Baxter Stock Around $80?

@forbes.com 4 years ago

Will Teva Stock Rebound After A 10% Fall In A Month?

@forbes.com 4 years ago

AT&T Stock Will Not Go Back To Its Pre-Covid High

@forbes.com 4 years ago

Stock Offering 60% Upside: Strategic Education

@forbes.com 5 years ago

Biotechnology In the Time of COVID-19: Past, Present, and Future

@forbes.com 3 years ago

Vertex Pharmaceuticals Stock Is Likely To Rebound From $180 Levels Currently

@forbes.com 4 years ago

Should You Buy Xerox Stock At $24 Levels?

@forbes.com 4 years ago

Recessionary Environment To Inhibit Further Gains In Paychex Stock

@forbes.com 4 years ago

Molson Coors Stays Flat As Market Rises, But The Tide Is Set To Turn

@reuters.com 5 years ago

Negative $40 oil reflects panic - and U.S. crude market economic reality

@forbes.com 3 years ago

Is A Recovery Imminent In Haemonetics Stock After Falling 40% This Year?

@forbes.com 4 years ago

Should You Buy BioMarin Pharmaceutical Stock At $78?

@forbes.com 4 years ago

Should You Buy CVS Health Stock At $70?

@forbes.com 4 years ago

AT&T: Stock With 20% Growth Potential

@forbes.com 3 years ago

Kirby Stock Performance In The Pandemic vs 2008

@forbes.com 4 years ago

Should You Buy uniQure Stock At $30?

@realclearpolitics.com 4 years ago

Covid Restrictions a Constitutional Stress Test

@theatlantic.com 5 years ago

Doug Jones on the South's Confederate Past and Pandemic Present